Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Area of Science:

• Biotechnology
• Oncology
• Immunotherapy

Background:

• Chimeric antigen receptor (CAR) cell therapies have advanced hematological cancer treatment, with FDA/EMA-approved products available.
• Significant challenges with CAR-cell therapies include cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
• Cell-free CAR-engineered extracellular vesicles (CAR-EVs) present advantages like improved tumor infiltration and reduced CRS/ICANS risks.

Purpose of the Study:

• To develop a scalable platform for producing tunable CAR-EVs.
• To engineer and pre-condition EV producer cells (CAR-T, CAR-NK).
• To establish methods for CAR-EV isolation, enrichment, and analysis.

Main Methods:

• Engineering and pre-conditioning of EV producer cells (CAR-T, CAR-NK).
• Isolation and enrichment of CAR-EVs using GMP-grade ion-exchange chromatography (IEX).
• Automated high-throughput EV subpopulation analysis and in vitro functional cytotoxic assays.

Main Results:

• Development of a scalable platform for producing tunable CAR-EVs.
• Validation of the platform using CAR-NK-EVs and CAR-T-EVs against hematological and solid tumor cell lines.
• Demonstration of CAR-EVs' functional cytotoxic activity in vitro.

Conclusions:

• The developed CAR-EV platform facilitates rapid production of off-the-shelf therapeutic EVs.
• This platform enables tailoring CAR-EVs for specific cancer indications.
• CAR-EVs show potential for reducing adverse effects associated with CAR-cell therapies.